CareDx Presents Findings from The SHORE Study, HeartCare Outperforms dd-cfDNA Alone In Identifying Rejection And Patients Experienced Fewer Biopsies
Portfolio Pulse from Benzinga Newsdesk
CareDx, Inc. (NASDAQ: CDNA) announced findings from the SHORE study, showing that its HeartCare® solution outperforms dd-cfDNA alone in identifying acute cellular rejection in heart transplant patients. The study, published in The Journal of Heart and Lung Transplantation, indicates that HeartCare® leads to fewer biopsies and excellent clinical outcomes.

May 16, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CareDx's HeartCare® has been shown to outperform dd-cfDNA alone in identifying acute cellular rejection in heart transplant patients, leading to fewer biopsies and excellent clinical outcomes. This could enhance the company's reputation and potentially increase demand for its products.
The SHORE study's positive results for HeartCare® could boost CareDx's market position and drive higher adoption of its products, potentially leading to increased revenues and a positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100